6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OFFOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September, 2022

Commission File Number 000-29962

Kazia Therapeutics Limited

(Translation of registrant’s name into English)

ThreeInternational Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ☒                 Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

On September 8, 2022, Kazia Therapeutics Limited (the “Company”) issued an ASX announcement regarding certain changes to the Company’s directors’ ownership interest in the Company. A copy of the document detailing this information is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

EXHIBIT LIST

Exhibit	Description
99.1	Appendix 3Y: Change of Director’s Interest Notice

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Kazia Therapeutics Limited (Registrant)
/s/ Karen Krumeich
Karen Krumeich
Chief Financial Officer

Date: 8 September 2022

EX-99.1

Exhibit 99.1

Appendix3Y

Change ofDirector’s Interest Notice

Rule 3.19A.2

Appendix3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s propertyand may be made public.

Introduced 30/09/01 Amended 01/01/11

IName of entity Kazia Therapeutics Limited (“Kazia”)
rsN 37 063 259 754

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr lain Ross
Date of last notice	21 December 2021

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest<br><br><br>(including registered holder)<br> <br><br><br><br>Note: Provide details of the circumstances giving rise to the relevant interest.
Date of change	6 September 2022
No. of securities held prior to change	1,075,001 ordinary shares<br> <br><br><br><br>400,000 unlisted options
Class	Ordinary shares
Number acquired	175,000
Number disposed	N/A

+See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix3Y

Change of Director’s Interest Notice

Value/Consideration<br> <br><br><br><br>Note: If consideration is non-cash, provide details and estimated valuation	175,000 ordinary shares at $0.2207 per share
No. of securities held after change	1,250,001 ordinary shares<br> <br><br><br><br>400,000 unlisted options
Nature of change<br> <br><br><br><br>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan,<br>participation in buy-back	Purchased on market

Part 2 - Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of“notifiable interest of a director” should be disclosed in this part.

Detail of contract
Nature of interest
Name of registered holder (if issued securities)
Date of change
No. and class of securities to which interest related prior to change<br><br><br><br> <br>Note: Details are only required for a contract in relation to which the interest has<br>changed

+See chapter 19 for defined terms.

Appendix 3Y Page 2	01/01/2011

Appendix3Y

Change of Director’s Interest Notice

Interest acquired
Interest disposed
Value/Consideration<br> <br><br><br><br>Note: If consideration is non-cash, provide details and an estimated valuation
Interest after change

Part 3 - +closed period

Were the interests in the securities or contracts detailed above<br><br><br>traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to<br><br><br>proceed during this period?	N/A
If prior written clearance was provided, on what date was this<br><br><br>provided?

+See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 3

Appendix3Y

Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomeASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

IName of entity Kazia Therapeutics Limited (“Kazia”)
rsN 37 063 259 754

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Steven Coffey
Date of last notice	21 December 2021

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest<br><br><br>(including registered holder)<br> <br><br><br><br>Note: Provide details of the circumstances giving rise to the relevant interest.	Fortune 501 Pty Limited (SR Coffey Superfund) Steven Coffey<br><br><br>Coffey Family Investments Pty Limited
Date of change	6 & 7 September 2022
No. of securities held prior to change	426,250 ordinary shares (indirect)<br> <br><br><br><br>8,015 ordinary shares (direct)<br> <br>400,000 unlisted options<br>(direct)<br> <br><br> <br>50,000 ordinary shares
Class	Ordinary shares
Number acquired	50,000 ordinary shares (indirect)
Number disposed

+See chapter 19 for defined terms.

01/01/20n Appendix 3Y Page 1

Appendix3Y

Change of Director’s Interest Notice

Value/Consideration<br> <br><br><br><br>Note: If consideration is non-cash, provide details and estimated valuation	73,372 ordinary shares at $0.2097 per share<br><br><br>26,628 ordinary shares at $0.235 per share
No. of securities held after change	426,250 ordinary shares (indirect)<br> <br><br><br><br>8,015 ordinary shares (direct)<br> <br>400,000 unlisted options<br>(direct)<br> <br><br> <br>100,000 ordinary shares (indirect)
Nature of change<br> <br><br><br><br>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation inbuy-back	Purchased on market

Part 2 - Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract
Nature of interest
Name of registered holder (if issued securities)
Date of change
No. and class of securities to which interest related prior to change<br><br><br><br> <br>Note: Details are only required for a contract in relation to which the interest haschanged

+See chapter 19 for defined terms.

Appendix 3Y Page 2	01/01/2011

Appendix3Y

Change of Director’s Interest Notice

Interest acquired
Interest disposed
Value/Consideration<br> <br><br><br><br>Note: If consideration is non-cash, provide details and an estimated valuation
Interest after change

Part 3 - +closed period

Were the interests in the securities or contracts detailed above<br><br><br>traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to<br><br><br>proceed during this period?	N/A
If prior written clearance was provided, on what date was this<br><br><br>provided?

+See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 3

Appendix3Y

Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomeASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

IName of entity Kazia Therapeutics Limited (“Kazia”)
rsN 37 063 259 754

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr James Garner
Date of last notice	21 December 2021

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest<br><br><br>(including registered holder)<br> <br>Note: Provide details of the<br>circumstances giving rise to the relevant interest.
Date of change	6 & 7 September 2022
No. of securities held prior to change	500,000 ordinary shares<br> <br><br><br><br>4,500,000 unlisted options
Class	Ordinary shares
Number acquired	100,000 ordinary shares
Number disposed	N/A

+See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix3Y

Change of Director’s Interest Notice

Value/Consideration<br> <br><br><br><br>Note: If consideration is non-cash, provide details and estimated valuation	50,000 ordinary shares at an average price of $0.2250<br> <br><br><br><br>50,000 ordinary shares at an average price of $0.2377
No. of securities held after change	600,000 ordinary shares<br> <br><br><br><br>4,500,000 unlisted options
Nature of change<br> <br><br><br><br>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestmentplan, participation in buy-back	Purchased on market

Part 2 - Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract
Nature of interest
Name of registered holder<br> <br>(if issuedsecurities)
Date of change

+See chapter 19 for defined terms.

Appendix 3Y Page 2	01/01/2011

Appendix3Y

Change of Director’s Interest Notice

No. and class of securities to which interest related prior to change<br><br><br><br> <br>Note: Details are only required for a contract in relation to which the interest has<br>changed
Interest acquired
Interest disposed
Value/Consideration<br> <br><br><br><br>Note: If consideration is non-cash, provide details and an estimated valuation
Interest after change

Part 3 - +closed period

Were the interests in the securities or contracts detailed above<br><br><br>traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to<br><br><br>proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?

+See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 3

Appendix3Y

Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomeASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

IName of entity Kazia Therapeutics Limited (“Kazia”)
rsN 37 063 259 754

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr Bryce Carmine
Date of last notice	21 December 2021

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder)<br><br><br><br> <br>Note: Provide details of the circumstances giving rise to the relevant<br>interest.
Date of change	6 September 2022
No. of securities held prior to change	419,861 ordinary shares<br> <br><br><br><br>400,000 unlisted options
Class	Ordinary shares
Number acquired	120,000 Ordinary shares
Number disposed	N/A

+See chapter 19 for defined terms.

01/01/20n Appendix 3Y Page 1

Appendix3Y

Change of Director’s Interest Notice

Value/Consideration<br> <br><br><br><br>Note: If consideration is non-cash, provide details and estimated valuation	120,000 ordinary shares at $0.235
No. of securities held after change	539,861 ordinary shares<br> <br><br><br><br>400,000 unlisted options
Nature of change<br> <br><br><br><br>Example: on-market trade, off-market trade, exercise of options, issue ofsecurities under dividend reinvestment plan, participation in buy-back	Purchased on market

Part 2 - Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract
Nature of interest
Name of registered holder (if issued securities)
Date of change
No. and class of securities to which interest related prior to change<br><br><br><br> <br>Note: Details are only required for a contract in relation to which the interest haschanged

+See chapter 19 for defined terms.

Appendix 3Y Page 2	01/01/2011

Appendix3Y

Change of Director’s Interest Notice

Interest acquired
Interest disposed
Value/Consideration<br> <br><br><br><br>Note: If consideration is non-cash, provide details and an estimated valuation
Interest after change

Part 3 - +closed period

Were the interests in the securities or contracts detailed above<br><br><br>traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to<br><br><br>proceed during this period?	N/A
If prior written clearance was provided, on what date was this<br><br><br>provided?

+See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 3